TIAA CREF Investment Management LLC Acquires 37,672 Shares of Global Blood Therapeutics, Inc. (GBT)

TIAA CREF Investment Management LLC boosted its stake in shares of Global Blood Therapeutics, Inc. (NASDAQ:GBT) by 40.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 130,606 shares of the company’s stock after buying an additional 37,672 shares during the period. TIAA CREF Investment Management LLC owned 0.30% of Global Blood Therapeutics worth $4,813,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in GBT. Wellington Management Group LLP increased its position in shares of Global Blood Therapeutics by 10.8% in the first quarter. Wellington Management Group LLP now owns 2,321,123 shares of the company’s stock worth $85,534,000 after buying an additional 225,994 shares during the last quarter. Fernwood Investment Management LLC boosted its stake in Global Blood Therapeutics by 356.7% in the first quarter. Fernwood Investment Management LLC now owns 262,510 shares of the company’s stock worth $9,673,000 after buying an additional 205,026 shares during the period. FMR LLC boosted its stake in Global Blood Therapeutics by 2.9% in the first quarter. FMR LLC now owns 5,759,471 shares of the company’s stock worth $212,236,000 after buying an additional 162,004 shares during the period. Teachers Advisors LLC boosted its stake in Global Blood Therapeutics by 426.2% in the first quarter. Teachers Advisors LLC now owns 156,195 shares of the company’s stock worth $5,756,000 after buying an additional 126,513 shares during the period. Finally, EAM Investors LLC bought a new stake in Global Blood Therapeutics during the first quarter worth approximately $3,546,000. Institutional investors and hedge funds own 72.65% of the company’s stock.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) traded up 0.35% during midday trading on Wednesday, hitting $28.60. 613,093 shares of the stock were exchanged. The firm’s 50 day moving average price is $28.15 and its 200 day moving average price is $29.09. Global Blood Therapeutics, Inc. has a 12 month low of $13.35 and a 12 month high of $41.15. The company’s market cap is $1.25 billion.

Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings data on Monday, August 7th. The company reported ($0.55) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.61) by $0.06. During the same quarter in the previous year, the business posted ($0.58) earnings per share. On average, equities research analysts forecast that Global Blood Therapeutics, Inc. will post ($2.43) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://baseballnewssource.com/markets/global-blood-therapeutics-inc-gbt-shares-bought-by-tiaa-cref-investment-management-llc-updated-updated-updated/1252106.html.

A number of research firms have recently commented on GBT. Janney Montgomery Scott started coverage on shares of Global Blood Therapeutics in a research report on Monday, May 1st. They issued a “buy” rating and a $37.00 target price for the company. BidaskClub upgraded shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 5th. ValuEngine upgraded shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 10th. Cowen and Company restated an “outperform” rating and set a $83.00 price target on shares of Global Blood Therapeutics in a research report on Monday. Finally, Wedbush restated an “outperform” rating and set a $73.00 price target on shares of Global Blood Therapeutics in a research report on Tuesday, May 2nd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $49.73.

In related news, Director Deval L. Patrick sold 27,053 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $29.69, for a total value of $803,203.57. Following the sale, the director now owns 12,053 shares of the company’s stock, valued at $357,853.57. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Jung Choi sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $30.00, for a total transaction of $90,000.00. Following the completion of the sale, the insider now directly owns 143,255 shares in the company, valued at approximately $4,297,650. The disclosure for this sale can be found here. Company insiders own 5.30% of the company’s stock.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets
Injury to CC Sabathia Adds to Yankees’ Concerns
Injury to CC Sabathia Adds to Yankees’ Concerns


Leave a Reply

 
© 2006-2017 BBNS.